An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...
Saved in:
Main Authors: | , , , , , |
---|---|
格式: | 圖書 |
出版: |
Taylor & Francis Group,
2023-08-01T00:00:00Z.
|
主題: | |
在線閱讀: | Connect to this object online. |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
索引號: |
A1234.567 |
---|---|
復印件 1 | 可用 |